- Home
- XLO vs CTSO Comparison
XLO vs CTSO Comparison
Compare XLO & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XLO
- CTSO
- Stock Information
- Founded
- XLO 2016
- CTSO 1997
- Country
- XLO United States
- CTSO United States
- Employees
- XLO N/A
- CTSO N/A
- Industry
- XLO Biotechnology: Pharmaceutical Preparations
- CTSO Medical/Dental Instruments
- Sector
- XLO Health Care
- CTSO Health Care
- Exchange
- XLO Nasdaq
- CTSO Nasdaq
- Market Cap
- XLO 41.8M
- CTSO 45.3M
- IPO Year
- XLO 2021
- CTSO N/A
- Fundamental
- Price
- XLO $0.75
- CTSO $0.84
- Analyst Decision
- XLO Buy
- CTSO Buy
- Analyst Count
- XLO 1
- CTSO 2
- Target Price
- XLO $2.00
- CTSO $5.38
- AVG Volume (30 Days)
- XLO 996.7K
- CTSO 133.1K
- Earning Date
- XLO 11-13-2025
- CTSO 11-13-2025
- Dividend Yield
- XLO N/A
- CTSO N/A
- EPS Growth
- XLO N/A
- CTSO N/A
- EPS
- XLO N/A
- CTSO N/A
- Revenue
- XLO $31,804,000.00
- CTSO $36,979,520.00
- Revenue This Year
- XLO $519.70
- CTSO $11.93
- Revenue Next Year
- XLO $44.57
- CTSO $21.22
- P/E Ratio
- XLO N/A
- CTSO N/A
- Revenue Growth
- XLO 588.40
- CTSO 23.89
- 52 Week Low
- XLO $0.62
- CTSO $0.60
- 52 Week High
- XLO $1.70
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- XLO 46.63
- CTSO 59.41
- Support Level
- XLO $0.73
- CTSO $0.60
- Resistance Level
- XLO $0.81
- CTSO $0.85
- Average True Range (ATR)
- XLO 0.06
- CTSO 0.07
- MACD
- XLO -0.00
- CTSO 0.02
- Stochastic Oscillator
- XLO 51.26
- CTSO 92.08
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.